Business News

Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?

FinSiddhi

Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant careful consideration despite strong investor interest.
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.

Related Posts

In 1902, a three-year-old girl arrived on Georgia’s Cumberland Island; she remained closely tied to it for decades and later opposed large-scale development

Lucy Carnegie Ricketson Ferguson spent her life on Cumberland Island, a place she fought to preserve. Developers threatened the island’s natural beauty in the late 1960s, prompting a conservation campaign. Carnegie descendants and conservation groups united to protect the island from large-scale development. Congress established Cumberland Island National Seashore in 1972, preserving its unique landscape….

New York’s Bluebelt wetlands saved $80 million in infrastructure costs

In an innovative move, New York City has turned to its natural wetlands for stormwater management, resulting in significant cost savings. The Bluebelt initiative has replaced expensive underground drainage systems with revitalized waterways, integrating both green and grey infrastructure to manage runoff efficiently. This strategic framework not only safeguards and extends essential wetland areas but…